EyePoint Pharmaceuticals (EYPT): Valuation Update Following Positive Phase 3 DURAVYU Safety Review [Yahoo! Finance]
EyePoint Pharmaceuticals, Inc. (EYPT)
Last eyepoint pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
This marks a key step in ongoing clinical progress. See our latest analysis for EyePoint Pharmaceuticals. With the successful safety milestone for DURAVYU front and center, EyePoint's share price has surged 77.8% year-to-date, reflecting renewed confidence around its late-stage pipeline. The company has also granted stock options to new hires recently, adding to this sense of momentum. For context, the stock's 1-year total shareholder return now sits at an impressive 59.5%, and three-year total returns are up over 320%, a run that's hard to ignore. If EyePoint's recent clinical progress has piqued your interest, you may want to explore other biotech and pharma stocks in our hand-picked list: See the full list for free. With shares now trading well below consensus analyst price targets, EyePoint's breakout begs the question: is there still upside potential ahead for investors, or is all that future growth already reflected in the stock? Most Popular Narrative: 58.5% Undervalu
Show less
Read more
Impact Snapshot
Event Time:
EYPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EYPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EYPT alerts
High impacting EyePoint Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
EYPT
News
- Eyepoint Pharmaceuticals (NASDAQ:EYPT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.MarketBeat
- EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration [Yahoo! Finance]Yahoo! Finance
- EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular DegenerationGlobeNewswire
- EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report [Yahoo! Finance]Yahoo! Finance
EYPT
Earnings
- 11/5/25 - Miss
EYPT
Sec Filings
- 12/5/25 - Form 4
- 12/4/25 - Form 144
- 12/1/25 - Form 4
- EYPT's page on the SEC website